Uncategorized
Ocular Therapeutix begins enrollment for phase 3 clinical trial with OTX-TP
Ocular Therapeutix announced the enrollment of the first patient in the first of two planned phase 3 clinical trials with OTX-TP for the treatment of glaucoma and ocular hypertension. OTX-TP, which is placed in the canaliculus, is designed to deliver travoprost to the ocular surface for up to 90 days.